Thomas' hematopoietic cell transplantation : stem cell transplantation /
Annotation -- Fully revised for the fifth edition, this outstanding reference on bone marrow transplantation is an essential, fieldleading resource. -- Extensive coverage of the field, from the scientific basis for stemcell transplantation to the future direction of research -- Combines the knowledg...
Saved in:
| Other Authors: | , , , |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Chichester, West Sussex, United Kingdom ; Hoboken, New Jersey :
John Wiley & Sons Inc.,
2015.
|
| Edition: | Fifth edition. |
| Subjects: | |
| Online Access: | CONNECT |
Table of Contents:
- Volume 1 ; Title Page; Copyright Page; Contents; Contributors; Preface to the First Edition; Preface to the Fifth Edition; Tribute; List of Abbreviations; Section 1 History and Use of Hematopoietic Cell Transplantation; Chapter 1 A History of Allogeneic and Autologous HematopoieticCell Transplantation ; How it all began; History of allogeneic HCT; 1949-1956: The humoral versus the cellular hypotheses; 1956-1959: Early efforts in clinical marrow transplantation; 1955-1967: Progress in animal models of allogeneic HCT; 1968-1975: The beginning of the modern era of human marrow transplantation.
- 1976-1989: Widening application of allogeneic marrow grafting for human patients1989-1999: Progress in the prevention and therapy of CMV disease. New sources of grafts for allogeneic HCT; 2000-present: Reduced intensity regimens (RIC) allow transplantation of elderly and medically infirm patients. Hematologic grafts induce tolerance for solid organ transplantation; History of autologous HCT; 1958-1964: From pre-clinical studies to first clinical transplant efforts ; 1978-1995: The beginning of an era of promising results in autologous HCT.
- 1986-2004: Circulating stem cells and cloned hematopoietic growth factors1982-2001: Testing for minimal residual disease and efforts to purge grafts for autologous HCT; 1986-1999: High-dose chemotherapy and transplantation of autologous hematopoietic cells for patients with breast cancer ; 1993-present: Research to improve preparatory regimens and efforts to consolidate post-HCT remissions ; Conclusion; References; Chapter 2 Uses and Growth of Hematopoietic Cell Transplantation; Introduction; Changing indications for HCT; Changes in patient selection; Hematopoietic cell sources.
- Autologous transplantationAllogeneic transplantation; Transplantation regimens and supportive care; Long-term survivors; Addressing barriers to use of HCT; Assessing and improving results of HCT; References; Section 2 Scientific Basis or Hematopoietic Cell Transplantation; Section 2a Hematopoiesis and Stem Biology Transplantation; Chapter 3 Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Pluripotent Stem Cells; Introduction; Generation of HSCs from ESCs; What have we learned from murine ESCs?; Derivation of HSCs from hPSCs; Derivation of hemangioblasts from hESCs.
- Derivation of blood-specific lineages from hPSCsT cells; B cells; NK cells; Macrophages; Dendritic cells; Erythroid cells; Megakaryocytes/platelets; Isolation and/or expansion of hPSC-derived HSCs; Are PSC-derived hematopoietic progenitors capable of engraftment and hematopoietic repopulation?; Transplantation of HSCs derived from mPSCs; Transplantation of HSCs derived from human PSCs; Can we generate immunologically compatible HSCs?; Creation of a global hPSC bank; Immune privileged?; Pluripotent stem cells tailor-made by reprogramming patients' somatic cells (iPS).
